We must work together to increase patient access to safe, effective and more-affordable medicines.
AAM advocates on behalf of our members, protecting and enhancing their ability to manufacture, compete and innovate. AAM educates stakeholders — from lawmakers to the media to patients and providers — about the role of generics and biosimilars in health care. AAM advises the government and our members how policies affect our industry and the patients we serve.
Together, we assure access to safe, quality, effective medicines for patients. AAM’s membership convenes for meetings, workshops, networking and education throughout the year. AAM provides opportunities for the industry to meet and learn from the government agencies that regulate it. AAM members receive all association benefits including real-time reporting and analysis on issues, policies and market trends affecting accessible medicines, including small-molecule generics, complex generics and biosimilars. We hope you will join us.
View the AAM Regular Member benefits in our Fact Sheet: